Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 7, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 6, 2026 — +32.7% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$885.00 – $910.00Entry zone — fair-value band

$904.25Published — price the day we called it

$1,067.01Target — the price the thesis aimed for

$1,238.00Peak — highest point inside the window, not a realized return

$1,200.06Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 45 days.

At window close

+32.7%

realized, from the publication price to the last close inside the window

Peak gain

+36.9%

peak, from the publication price — not a realized return

S&P 500, same window

+14.3%

SPY over the identical days, dividend-adjusted

Window close

$1,200.06

last close inside the window, ended July 6, 2026

Peak price

$1,238.00

peak on June 29, 2026 — not a realized return

Days to target

The thesis — published April 7, 2026

Predicted growth

+18%

over the measurement window

Target price

$1,067.01

the price the thesis aimed for

Entry zone

$885.00 – $910.00

the fair-value band we waited for

Price at publication

$904.25

published April 7, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is getting real, concrete support from recent approvals, deals, and acquisitions that strengthen demand for its obesity, diabetes, and other drug programs. The stock pulled back below its recent trend after a reset, creating a clearer, calmer path for a steady recovery over the next few months if healthcare stocks lead again. That combination of real news and a cooler entry point makes the setup unusually durable short-term.

Primary drivers

Strong demand for obesity and diabetes treatments
Recent approvals, deals, and acquisitions add near-term drivers
Price has pulled back below recent trend after a reset
Healthcare sector strength can quickly lift the stock

How it played out

LLY: target reached in 45 days

Lyra published an 18% growth thesis from $904.25, with a $1,067.01 target. The thesis expected a steady recovery over the next few months. It pointed to demand for obesity and diabetes treatments, recent approvals, deals and acquisitions, a pullback below the recent trend, and possible healthcare sector strength.

LLY reached the target in 45 days. It later peaked at $1,238 on June 29, a 36.9% gain. The stock ended the window at $1,200.06, still above the target. The published thesis played out and exceeded its stated price objective.

What happened during the window

On April 30, Eli Lilly reported its first-quarter 2026 results and updated its full-year guidance. On May 6, the company announced an additional $4.5 billion investment across two Indiana manufacturing sites.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals